逍遥方作为中风后抑郁辅助治疗的疗效与安全性：一项Meta分析
Efficacy and Safety of Xiaoyao Formula as an Adjuvant Treatment for Post-Stroke Depression: A Meta-Analysis.
作者信息
Jin Xin, Jiang Menglin, Gong Dandan, Chen Yuehua, Fan Yu
机构信息
Institute of Molecular Biology & Translational Medicine, the Affiliated People's Hospital, Jiangsu University, No. 8 Dianli Road, Zhenjiang, Jiangsu 212002, PR China.
Department of Nuclear Medicine, Affiliated Hospital of Jiangsu University, No. 438 Jiefang Road, Zhenjiang, Jiangsu 212001, PR China.
出版信息
Explore (NY). 2018 May-Jun;14(3):224-229. doi: 10.1016/j.explore.2017.12.007. Epub 2018 Mar 7.
OBJECTIVE
To systematically evaluate the efficacy and safety of Xiaoyao formula (XYF) as an adjuvant treatment of post-stroke depression (PSD) by conducting a meta-analysis.
METHODS
Pubmed, Embase, Cochrane Library, CNKI, VIP, and Wanfang databases were searched up to May 2016. Randomized controlled trials investigating XYF plus antidepressants versus antidepressants alone for patients with PSD were considered.
RESULTS
A total of 607 PSD patients were identified from 7 trials. Adjuvant treatment with XYF had additional benefits in terms of improved total response rates (risk ratio [RR] 1.21; 95% confidence interval [CI]: 1.12-1.30), reduced Hamilton's depressive scale (weighted mean difference [WMD] -5.21; 95% CI: -7.48 to -2.95), and decreased Scandinavian Stroke Scale (WMD -6.35; 95% CI: -8.27 to -4.43). No serious adverse events were observed in any of the included trials.
CONCLUSIONS
Adjuvant treatment with XYF appears to have additional benefits in the treatment of PSD, without increasing serious adverse events.
目的
通过进行一项荟萃分析，系统评价逍遥方（XYF）作为中风后抑郁（PSD）辅助治疗的疗效和安全性。
方法
检索截至2016年5月的Pubmed、Embase、Cochrane图书馆、中国知网、维普和万方数据库。纳入比较XYF联合抗抑郁药与单纯抗抑郁药治疗PSD患者的随机对照试验。
结果
从7项试验中总共识别出607例PSD患者。逍遥方辅助治疗在提高总有效率（风险比[RR]1.21；95%置信区间[CI]：1.12 - 1.30）、降低汉密尔顿抑郁量表评分（加权均数差[WMD] - 5.21；95%CI： - 7.48至 - 2.95）以及降低斯堪的纳维亚卒中量表评分（WMD - 6.35；95%CI： - 8.27至 - 4.43）方面具有额外益处。在任何纳入试验中均未观察到严重不良事件。
结论
逍遥方辅助治疗似乎在PSD治疗中具有额外益处，且不增加严重不良事件。
Zotero 插件